IFNG and prostate cancer: This suggests a key difference between hematologic and solid tumor CAR-T therapies, although the role of IFN-γ in CAR-T in humans needs further study and the specific clinical scenario presented in this case report (i.e., PSCA target, use of an activation switch, prostate cancer microenvironment) may limit a broad conclusion.